David A. Siegel Ovid Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.43 - $1.86 $6,149 - $7,998	-4,300 Reduced 23.5%	14,000 $26,000
Q3 2022 Nov 14, 2022	SELL	$1.85 - $2.26 $10,175 - $12,429	-5,500 Reduced 23.11%	18,300 $34,000
Q2 2022 Aug 15, 2022	SELL	$1.69 - $3.31 $17,914 - $35,086	-10,600 Reduced 30.81%	23,800 $51,000
Q1 2022 May 16, 2022	SELL	$2.65 - $3.49 $33,655 - $44,323	-12,700 Reduced 26.96%	34,400 $108,000
Q4 2021 Feb 14, 2022	SELL	$3.13 - $3.73 $190,617 - $227,157	-60,900 Reduced 56.39%	47,100 $151,000

Q3 2021 Nov 15, 2021	SELL	$3.31 - $4.04 $742,102 - $905,768	-224,200 Reduced 67.49%	108,000 $363,000
Q2 2021 Aug 16, 2021	BUY	$3.3 - $4.49 $41,580 - $56,574	12,600 Added 3.94%	332,200 $1.3 Million
Q1 2021 May 17, 2021	SELL	$2.42 - $4.47 $662,596 - $1.22 Million	-273,800 Reduced 46.14%	319,600 $1.29 Million
Q4 2020 Feb 16, 2021	BUY	$2.28 - $6.84 $969,455 - $2.91 Million	425,200 Added 252.79%	593,400 $1.37 Million
Q3 2020 Nov 16, 2020	BUY	$5.39 - $8.24 $906,598 - $1.39 Million	168,200 New	168,200 $965,000
Q2 2020 Aug 14, 2020	SELL	$2.67 - $7.91 $62,478 - $185,094	-23,400 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.03 - $4.35 $8,526 - $18,270	4,200 Added 21.88%	23,400 $70,000
Q4 2019 Feb 14, 2020	BUY	$2.08 - $5.06 $39,936 - $97,151	19,200 New	19,200 $80,000

43.2M

5.9K

300

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $52.8M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.